Showing 15 posts of 552 posts found.


Sanofi’s RSV drug sees Phase III clinical trial success

April 26, 2021
Sales and Marketing AstraZeneca, Sanofi

Sanofi have announced positive topline results from the Phase III MELODY trial into nirsevimab, which demonstrated protection against respiratory syncytial …

Sanofi signs €414 million deal for C4XD oral IL-17A inhibitor programme

April 19, 2021
Sales and Marketing Sanofi

Sanofi has signed an exclusive worldwide licensing agreement with C4X Discovery Limited for C4XD’s oral pre-clinical IL-17A inhibitor programme, which …

Sanofi multiple myeloma drug approved for second indication by EC

April 19, 2021
Sales and Marketing European Commission, Sanofi, Sarclisa, pharma, pharma news

The European Commission (EC) has approved a second indication of Sanofi’s Sarclisa drug for the treatment of adult patients with …

Sanofi to invest €400 million on Singapore vaccine production site

April 12, 2021
Sales and Marketing Sanofi, Vaccine

Sanofi have today announced a €400 million investment to create a unique vaccine production centre in Singapore, in partnership with …

New Sanofi Sarclisa treatment for multiple myeloma approved by FDA

April 1, 2021
FDA, FDA Approval, Sanofi, Sarclisa, multiple myeloma

Sanofi’s Sarclisa drug has been approved by the FDA in combination with carfilzomib and dexamethasone (Kd) for the treatment of …


Phase III trial of Libtayo stopped early after positive overall survival results

March 15, 2021
Sales and Marketing Cancer, Libtayo, Regeneron, Sanofi

A Phase III trial of Sanofi and Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) will be stopped early after positive results demonstrated …

Sanofi and SIRION collaborate on AAV vector development to treat serious diseases

February 24, 2021
Research and Development AAV vectors, SIRION, Sanofi

SIRION Biotech and Sanofi have entered into an agreement to develop effective medicines for illnesses impacting major human organs.


FDA approves Regeneron & Sanofi’s Libtayo for advanced non-small cell lung cancer

February 23, 2021
Manufacturing and Production Cancer, Sanofi

The FDA has approved Regeneron & Sanofi’s PD-1 inhibitor Libtayo (cemiplimab-rwlc) for the first-line treatment of patients with advanced non-small …

GSK and Sanofi to begin new Phase II trial of their COVID-19 vaccine

February 22, 2021
Sales and Marketing COVID, COVID Vaccine, COVID-19, GSK, Sanofi

GlaxoSmithKline (GSK) and Sanofi are set to begin a new Phase II study of their COVID-19 vaccine candidate, following setbacks …


FDA approves Sanofi’s Libtayo for advanced basal cell carcinoma

February 10, 2021
Research and Development Cancer, FDA, Sanofi

The FDA has approved Sanofi’s PD-1 inhibitor Libtayo (cemiplimab-rwlc) as the first immunotherapy indicated for patients with advanced basal cell …


MHRA grants Promising Innovative Medicine Designation to Sanofi’s RSV drug

January 19, 2021
Manufacturing and Production MHRA, Sanofi

The MHRA has granted a Promising Innovative Medicine (PIM) Designation to Sanofi’s nirsevimab, which is being investigated a passive immunisation …

Sanofi to acquire Kymab for $1.1bn

January 11, 2021
Sales and Marketing Malin, Sanofi, kymab

Sanofi is to acquire clinical-stage biopharmaceutical company Kymab for approximately $1.1 billion. In addition to this upfront sum, Paris-headquartered Sanofi …


Sanofi/GSK COVID-19 vaccine development delayed after failing to induce strong response in over-50s

December 11, 2020
Medical Communications, Research and Development COVID-19, GSK, Sanofi, Vaccine

Sanofi and GlaxoSmithKline have taken the decision to delay the development programme for their adjuvanted recombinant protein-based COVID-19 vaccine after …

Dupixent becomes first systemic medicine approved in Europe for children with severe atopic dermatitis

November 30, 2020
Sales and Marketing Dupixent, EU, Europe, Sanofi

The European Commission has moved to expand the existing authorisation of Sanofi and Regeneron’s Dupixent (dupilumab) in the European Union …

NICE recommends Sanofi’s Cablivi for ultra-rare acute thrombotic thrombocytopenic purpura

November 12, 2020
Sales and Marketing NHS, NICE, Sanofi, pharma

Sanofi’s Cablivi (caplacizumab) has received recommendation from NICE for routine NHS use in England and Wales for the treatment of …

Latest content